E Varela1, M Antolín, F Guarner, R Verges, J Giralt, J-R Malagelada. 1. Digestive System Research Unit, University Hospital Vall d'Hebron, Autonomous University of Barcelona, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Barcelona, Spain.
Abstract
BACKGROUND: Acute intestinal toxicity is a frequent complication that may lead to interruption of treatment in patients undergoing pelvic radiotherapy. Reliable, non-invasive biological markers to evidence their severity are not yet available. AIM: To test faecal DNA and calprotectin as potential biomarkers of intestinal toxicity caused by pelvic radiotherapy. METHODS: Patients were categorized according to the location of the cancer as nonrectal (n = 25) and rectal (n = 27). Four stool samples were collected at weeks w0, w3, w5 (end of radiotherapy) and w7. Faecal DNA was determined by quantitative PCR and calprotectin by ELISA. Intestinal toxicity was scored according to the Common Toxicity Criteria. RESULTS: In the nonrectal group, acute diarrhoea toxicity was present in 80% of patients, faecal DNA increased 10-fold during radiotherapy (1.5 x 10(3) copies/mg dry weight, 9.5 x 10(2)-8.8 x 10(3) at w0, median and interquartile range vs. 1.3 x 10(4), 1.9 x 10(3)-3.9 x 10(4) at w5, P < 0.01), but was not recovered at w7 (3.4 x 10(3), 1.5 x 10(3)-4.1 x 10(4)) and calprotectin doubled during treatment at w3 and w5. No significant changes in faecal markers were found in the rectal group. CONCLUSION: Faecal excretion of human DNA and calprotectin increased during pelvic radiotherapy treatment, and may be a good objective biomarker of intestinal damage in nonrectal cancer patients.
BACKGROUND: Acute intestinal toxicity is a frequent complication that may lead to interruption of treatment in patients undergoing pelvic radiotherapy. Reliable, non-invasive biological markers to evidence their severity are not yet available. AIM: To test faecal DNA and calprotectin as potential biomarkers of intestinal toxicity caused by pelvic radiotherapy. METHODS:Patients were categorized according to the location of the cancer as nonrectal (n = 25) and rectal (n = 27). Four stool samples were collected at weeks w0, w3, w5 (end of radiotherapy) and w7. Faecal DNA was determined by quantitative PCR and calprotectin by ELISA. Intestinal toxicity was scored according to the Common Toxicity Criteria. RESULTS: In the nonrectal group, acute diarrhoea toxicity was present in 80% of patients, faecal DNA increased 10-fold during radiotherapy (1.5 x 10(3) copies/mg dry weight, 9.5 x 10(2)-8.8 x 10(3) at w0, median and interquartile range vs. 1.3 x 10(4), 1.9 x 10(3)-3.9 x 10(4) at w5, P < 0.01), but was not recovered at w7 (3.4 x 10(3), 1.5 x 10(3)-4.1 x 10(4)) and calprotectin doubled during treatment at w3 and w5. No significant changes in faecal markers were found in the rectal group. CONCLUSION: Faecal excretion of human DNA and calprotectin increased during pelvic radiotherapy treatment, and may be a good objective biomarker of intestinal damage in nonrectal cancerpatients.
Authors: Weiliang Huang; Jianshi Yu; Tian Liu; Gregory Tudor; Amy E Defnet; Stephanie Zalesak; Praveen Kumar; Catherine Booth; Ann M Farese; Thomas J MacVittie; Maureen A Kane Journal: Health Phys Date: 2020-11 Impact factor: 2.922
Authors: Jean-Bernard Delobel; Khemara Gnep; Juan David Ospina; Véronique Beckendorf; Ciprian Chira; Jian Zhu; Alberto Bossi; Taha Messai; Oscar Acosta; Joël Castelli; Renaud de Crevoisier Journal: PLoS One Date: 2017-06-22 Impact factor: 3.240
Authors: K R Slinger; A H Stewart; Z C T R Daniel; H Hall; H V Masey O'Neill; M R Bedford; T Parr; J M Brameld Journal: Animal Date: 2019-05-07 Impact factor: 3.240